Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Critical Care Cardiology
What are reasonable induction and paralytic agents to use during intubation for patients with acute MI and newly reduced LVEF with biventricular failure?
Related Questions
When differentiating and treating patients with shock (distributive/cardiogenic), how reliable would you consider the noninvasive clinical platform (EV1000) when derived from peripheral arterial lines?
What is your stepwise approach to supporting the RV in the setting of RV failure from unrevascularized RCA disease in an unstable patient in the absence of RP impella availability?
What factors do you consider for patients on an individual basis when establishing a post-cardiac arrest MAP goal after ROSC is achieved, considering some may benefit from higher MAP goals for optimal cerebral perfusion?
Is there any data to support the use of bivalirudin over heparin in patients on VA-ECMO without ongoing concerns for HIT?
What would be your approach to percutaneous intervention for acute plaque rupture and cardiogenic shock for a patient with cirrhosis and severe thrombocytopenia?
When do you usually introduce conversations regarding tracheostomy placement in patients with refractory status epilepticus, or other conditions where one may anticipate delayed awakening?
What is the role of mechanical circulatory support in mixed cardiogenic vasodilatory shock?
Is there any evidence to support further uptitration of dobutamine beyond 5mcg/kg/min for patients with advanced HF and/or cardiogenic shock, or should further investigation into potential MCS be considered at that point?
What has been your stepwise approach to oxygenation, including when to consider the use of inhaled nitric oxide or epoprostenol, in refractory hypoxemia due to cardiogenic pulmonary edema in patients who are otherwise not ECMO candidates?
What is your step-wise approach to differentiating SVT with aberrancy versus VT?
